Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock in an open-market transaction at a weighted average price of $24.38 per share. After the sale, she directly holds 27,567 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025.
Arcutis Biotherapeutics director Howard G. Welgus reported option exercises and share sales in the company’s stock. On June 15, 2026, he exercised stock options to acquire a total of 4,096 shares of common stock at exercise prices between $6.5223 and $8.63 per share.
On the same day and on June 17, 2026, he sold a total of 4,731 shares of common stock in open-market transactions at weighted average prices of $24.4093 and $25.67 per share, respectively. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Welgus directly owned 37,743 shares of Arcutis common stock.
Arcutis Biotherapeutics insider reported multiple sales of common stock and a small restricted-stock vesting. Howard Welgus disclosed sales totaling 21,240 shares executed on 04/01/2026, 05/01/2026, and 06/15/2026. The filing also notes a 635-share restricted stock vesting on 06/04/2026.
The three sales list proceeds of $238,800, $164,219.71, and $99,980.49 respectively in the provided lines. The filing is a Form 144 disclosure of these transactions under the issuer name Arcutis Biotherapeutics.
Arcutis Biotherapeutics submitted a Form 144 notice to sell 4,096 shares of Common Stock, with the filing dated 06/15/2026. The filing lists underlying grants described as stock option exercises (counts: 822, 1,019, 2,255) tied to earlier grant dates and shows two recent sales by Howard Welgus of 10,000 and 7,144 shares during April–May 2026.
Arcutis Biotherapeutics director Patrick J. Heron filed an amended insider report that corrects his indirect share holdings. A prior Form 4 understated the number of common shares indirectly held through Frazier Life Sciences X, L.P. by 2,646 shares due to a scrivener's error. After this correction, 27,448 shares of common stock are reported as indirectly held. These shares are owned of record by Frazier Life Sciences X, L.P., whose general partners are affiliated entities where Heron is one of two managing members. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Arcutis Biotherapeutics director Patrick J. Heron reported new equity awards. He received 5,778 Restricted Stock Units in connection with his service as a non-employee director at the 2026 annual stockholder meeting. Each RSU converts into one share of common stock upon vesting.
The RSUs vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service, and settlement has been deferred under a prior deferral election. Heron also received a stock option for 16,667 shares at an exercise price of $21.23 per share, vesting on the same schedule and expiring on June 5, 2036.
Following these awards, he holds 32,213 shares directly, in addition to indirect interests in shares held by The Heron Living Trust and several Frazier Life Sciences entities, for which he disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics director Sue-Jean Lin reported equity awards tied to board service. She received 5,778 Restricted Stock Units as of the company’s 2026 annual stockholder meeting, bringing her direct common stock holdings to 32,513 shares after the award.
Each RSU converts into one share of common stock upon vesting, which occurs on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under a prior deferral election.
Lin was also granted a stock option covering 16,667 shares of common stock at an exercise price of $21.23 per share. The option vests and becomes exercisable in full on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, contingent on continued board service through that date.
Arcutis Biotherapeutics director Howard G. Welgus received new equity awards as part of his board compensation. He acquired 5,778 Restricted Stock Units, each convertible into one share of common stock upon vesting, and a stock option for 16,667 shares at an exercise price of $21.23 per share.
The RSUs and option both vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service. Following the RSU grant, he directly holds 38,378 shares of common stock.
Arcutis Biotherapeutics director Leonard Keith R reported equity awards connected to his service as a non-employee director as of the company’s 2026 annual meeting. He received 5,778 Restricted Stock Units (RSUs), each convertible into one share of common stock upon vesting on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under an RSU Deferral Election Form adopted on October 28, 2025. He was also granted a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share, vesting on the same schedule and expiring on June 5, 2036. Following these awards, he holds 27,901 shares directly and 1,750 shares indirectly through the Leonard Family Trust dated August 28, 1996, for which he disclaims beneficial ownership except for his pecuniary interest.